Odovtos - International Journal of Dental Sciences ISSN Impreso: 1659-1046 ISSN electrónico: 2215-3411

OAI: https://revistas.ucr.ac.cr/index.php/Odontos/oai
Systemic conditions and treatments as risks to dental implant therapy
PDF (Español (España))


implant failure
systemic disease
implant failure
systemic disease

How to Cite

Arguedas Vega, N., & Alfaro Mayorga, E. (2014). Systemic conditions and treatments as risks to dental implant therapy. Odovtos - International Journal of Dental Sciences, (15), 61–68. Retrieved from https://revistas.ucr.ac.cr/index.php/Odontos/article/view/13736


The aim of this article is to describe posible risks and considerations described in the scientific literature for osseointegration in patients with systemic conditions, medical treatments or smoking habit and complications for osseointegration of diseases and / or systemic treatments, as well as smoking. The search and review of the literature available was made in the EBSCO, Ovid, Science Direct, PubMed, databases covering, all human studies that report survival of implants placed in patients who have at least one of the conditions studied, as well as other risks associated to surgical procedures in the placement of implants including. In the literature up to November 2012. The studies found are case reports and case series. No studies have compared patients with and without systemic conditions in a controlled manner. The level of evidence indicating absolute and relative contraindications for implant therapy in patients with the systemic level is low. Study is required primarily for patients with a bisphosphonate regimen.
PDF (Español (España))


Achong R. 2006. Implants in HIV-Positive Patients: 3 Case Reports. J Oral Maxillofac Surg. 64:1199-1203.

Hind A. Al-Ibrahim. 2012. Surgical and implant- supported fixed prosthetic treatment of a patient with ectodermal dysplasia: a case report. Spec Care Dentist. 32(1): 1-6.

Alcan T. 2006. Growth analysis of a patient with ectodermal dysplasia treated with endosseous implants: 6-year follow-up. Journal of Oral Rehabilitation 33: 175–182.

Allen M. 2012. A Review of Pharmaceutical Agents and Oral Bone Health: How Osteonecrosis of the Jaw Has Affected the Field. ONJ. ORAL CRANIOFAC TISSUE ENG. 2:101–113.

American Society of Anestesiologists . 2012. Physical Status Classificationhttp://www.asahq.org/Home/ For-Members/Clinical-Information/ASA- Physical-Status-Classification-System. Accesado agosto 27, 2012.

Arshad A. 1997. Implant Rehabilitation of Irradiated Jaws: A Preliminary Report. JOMI 12 (4) (523 - 526).

Asaadi G. 2007. Impact of local and systemic factors on the incidence of oral implant failures, up to abutment connection. J Clin Periodontol. 34: 610–617 .

Asaadi G. 2008. Impact of local and systemic factors on the incidence of late oral implant loss. Clin. Oral Impl. Res. 19, 670–676.

Asaadi G. 2008. Impact of local and systemic factors on the incidence of failures up to abutment connection with modified surface oral implants.J Clin Periodontol. 35: 51–57.

Awad J. 2008. Histologic analysis of human peri implant bone in type I osteoporosis.Journal of Oral Implantology. 34: 12-16.

Balshe A. 2008. The Effects of Smoking on the Survival of Smooth- and Rough-Surface Dental Implants. . Int J Oral Maillofac Surg.23:1117–1122.

Barasch A. 2011. Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN. J Dent Res. 90(4):439-44.

BaronM.2004.ImplantsinanHIV-positive Patient: A Case Report.Int J Oral Maxillofacial Implants. 19:425–430.

Bektor K. 2001. Growth Analysis of a Patient with Ectodermal Dysplasia Treated with Endosseous Implants: A Case Report. Int J Oral maxillofacial Implants. 16:864–874.

Bergendal B. 2008. Implant failure in young children with Ectodermal Dysplasia; A retrospective Evaluation of use and outcome of dental implant treatment in children in Sweden. Int J Oral maxillofacial Implants.23:520–524.

Bornstein M. 2009. Systemic Conditions and treatment as risk for implant therapy. Int J Oral Maxillofac Implants.24(SUPPL):12–27.

Crawford A. 1993.The Association Between the Failure of Dental Implants and Cigarette Smoking. JOMI 609-615.

Crawford A. 1996. Smoking and Implant Failure— Benefits of a Smoking Cessation Protocol. JOMI 756-759.

Dvorak G. 2011.Peri-implantitis and late implant failures in postmenopausal women: a cross- sectional study . J Clin Periodontol. 38: 950–955.

Edwards BJ. 2008. Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc. 139(12):1674-7.

Esser E, 2008. Dental Implants Following Radical Oral Cancer Surgery and Adjuvant Radiotherapy . JOMI 12( 4) :552 – 557.

Hellstein J. 2011. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis. Executive summary of recommendationsfrom the American Dental Association Council on Scientific Affairs. JADA 142(11):1243-1251.

Hwang D. 2006. Medical contraindications to implant therapy: part I: absolute contraindications. Implant Dent. 15(4):353-60.

Hwang D. 2007. Medical contraindications to implant therapy: Part II: Relative contraindications. Implant Dent. 16(1):13-23.

Isidor F. 1999. Outcome of treatment with implant- retained dental prosthe- ses in patients with Sjögren syndrome. Int J Oral Maxillofac. Implants. 14:736–743.

Jorkjend L. 2003. Periodontitis, caries and salivary factors in Sjögren’s syndrome patients compared to sex- and age-matched controls. .Journal of Oral Rehabilitation 30: 369–378

Khadivi V. 1999. Cardiovascular disease and treatment outcomes with osseointegration surgery. J Prosthet Dent. 81:533-6

Kunchur R, 2009. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg. 67(6):1167-73.

Kwon YD. 2011. Retrospective study of two biochemical markers for the risk assessment of oral bisphosphonate- related osteonecrosis of the jaws: can they be utilized as risk markers? Clin Oral Implants Res. 22: 30-37.

Landesberg R . 2009. Alternative indications for bisphosphonate therapy. J Oral Maxillofac Surg. 67(5 Suppl):27-34.

Lazarovici TS . 2010. Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates. J Oral Maxillofac Surg. 68(9):2241-7.

Lin T. 2012. The Effect of Cigarette Smoking and Native Bone Height on Dental Implants Placed Immediately in Sinuses Grafted by Hydraulic Condensation. Int J Periodontics Restorative Dent. 32:255–261.

Lindquist el al. 2007. A prospective 15 year foloow up of mandibular fixed prótesis suported by oseointegrated implants. Clinical results and margial bone loss. Clinical Oral Implant research. 7:329-336.

Mancha de la Plata. 2012. Osseointegrated Implant Rehabilitation of Irradiated Oral Cancer Patients. J Oral Maxillofac Surg . 70:1052-1063.

Marx RE. 2005.Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 63(11):1567-75.

Marx RE. 2007. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. (12):2397-410.

Mathews S. 2008. Oral Manifestations of Sjögren’s Syndrome . J Dent Res.87(4)308- 318.

Mavrokokki T. 2007. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 65(3):415-23.

McCracken M, Lemons JE. 2000 Bone response to titanium alloy implants placed in diabetic rats. Int J Oral Maxillofac Implants. 15:345–354.

Nabil S. 2011.Incidence and prevention of osteoradionecrosis after dental extraction in irradiated patients: a systematic review. Int. J. Oral Maxillofac. Surg. 40: 229–243.

Nevins ML. 1998. Wound healing around endosseous implants in experimental diabetes.Int J Oral Maxillofac Implants. 13:620–629.

Fiorellini JP. 2000. A retrospec- tive study of dental implants in diabetic patients. Int J Peri- odontics Restorative Dent. 20:366–373.

Olivieira M.2011. The success of endosseous implants in human immunodeficiency virus-positive patients receiving antiretroviral therapy. JADA 142(9):1010-1016

Peled M. 2003. Dental Implants in Patients With Type 2 Diabetes Mellitus: A Clinical Stud. Implant Dent. 12:116 –122.

Ruggiero SL . 2004. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 62(5):527-34.

Ruggiero SL. 2009. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-- 2009 update. J Oral Maxillofac Surg. 67(5 Suppl):2-12.

Schoen P. 2007. Rehabilitation of oral function in head and neck cancer patients after radiotherapy with implant-retained dentures: Effects of hyperbaric oxygen therapy. Oral Oncology. 43: 379– 388.

Strietzel F. 2006. Implant Prosthetic Treatment in HIV infected patients reciving highly active antiretroviral therapy: repost of cases. Int J Oral Maxillofacial Implants. 21:951–956.

Sugerman PB. 2002. Patient selection for endosseous dental implants: oral and systemic considerations. Int J Oral Maxillofac Implants. 17(2):191-201.

Tsolaky N. 2009. Outcomes of Dental Implants in Osteoporotic Patients. A Literature Review Journal of Prosthodontics . 18: 309–323.

Turkyilmaz I. 2010. One-Year Clinical Outcome of Dental Implants Placed in Patients With Type 2 Diabetes Mellitus: A Case Series. Implant Dent .19:323–329.

WesselJH.2008.Zoledronate,smoking,andobesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg. 66(4):625-31.



Download data is not yet available.